Skip to main content
Eris Lifesciences Limited logo

Eris Lifesciences Limited — Investor Relations & Filings

Ticker · ERIS ISIN · INE406M01024 LEI · 33580023SPXBP9PCKQ56 BSE.NS Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS ERIS

About Eris Lifesciences Limited

https://eris.co.in/

Eris Lifesciences Limited specializes in the development, manufacturing, and marketing of pharmaceutical products, primarily focusing on chronic and sub-chronic therapeutic areas. The company’s portfolio is concentrated on high-growth segments such as cardiovascular health, anti-diabetes, gastroenterology, and neurosciences. It also maintains a significant presence in vitamins, minerals, nutrients, and gynecology. Eris employs a specialty-focused business model, targeting medical specialists and super-specialists through a data-driven marketing approach. The organization emphasizes the management of lifestyle-related disorders and has expanded its capabilities into dermatology and nephrology through strategic acquisitions. Its operations integrate advanced manufacturing facilities with a robust distribution network to deliver branded generic formulations aimed at improving patient outcomes in long-term therapy management.

Recent filings

Filing Released Lang Actions
As Attached
Regulatory Filings Classification · 67% confidence The document is a stock exchange filing under SEBI Listing Obligations Disclosures, notifying the schedule of an investor/analyst meeting. It does not include financial statements or actual presentation slides, nor is it a proxy, dividend notice, earnings release, or management report. It is a routine regulatory announcement under Regulation 30. Therefore, it falls into the general Regulatory Filings category (RNS).
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is an intimation under SEBI Listing Regulations providing the schedule of analyst/institutional investor meetings. It is an operational disclosure to stock exchanges rather than a financial report, shareholder vote, or presentation itself. This falls under the catch-all Regulatory Filings category for miscellaneous compliance announcements.
2026-05-25 English
as attached
Report Publication Announcement Classification · 80% confidence The document is a stock exchange filing notifying that the recording of the earnings conference call for the quarter and fiscal year ended March 31, 2026 is now available on the company’s website. It does not contain financial data or the actual transcript, but simply announces the publication of the recording. This fits the definition of a Report Publication Announcement (RPA).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a stock exchange filing notifying BSE and NSE that the recording of the earnings conference call for Q4 and FY26 results is now available on the company’s website. It contains no financial data, no Q&A transcript, and is solely an announcement of a call recording in compliance with listing regulations. This falls under general regulatory or compliance announcements rather than an earnings release, transcript, or formal report, so it is classified as Regulatory Filings (RNS).
2026-05-20 English
as attached
Investor Presentation Classification · 94% confidence The document is an investor presentation submitted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains slide headings, quarterly and FY26 financial highlights, business segments, guidance, shareholding data and forward‐looking statements typical of an Investor Presentation, rather than an earnings release or annual report. Therefore, it is classified as an Investor Presentation (IP).
2026-05-20 English
as attached
Earnings Release Classification · 82% confidence The document is a statutory filing to BSE and NSE under SEBI LODR announcing the outcome of the Board meeting where the company approved and filed its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with an audit report and declaration of an interim dividend. This is an initial earnings announcement of periodical financial results rather than a full annual report or mere report publication notice, matching the definition of an Earnings Release. FY 2026
2026-05-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.